Cargando…
Non-Ceruloplasmin Copper Identifies a Subtype of Alzheimer’s Disease (CuAD): Characterization of the Cognitive Profile and Case of a CuAD Patient Carrying an RGS7 Stop-Loss Variant
Alzheimer’s disease (AD) is a type of dementia whose cause is incompletely defined. Copper (Cu) involvement in AD etiology was confirmed by a meta-analysis on about 6000 participants, showing that Cu levels were decreased in AD brain specimens, while Cu and non-bound ceruloplasmin Cu (non-Cp Cu) lev...
Autores principales: | Squitti, Rosanna, Catalli, Claudio, Gigante, Laura, Marianetti, Massimo, Rosari, Mattia, Mariani, Stefania, Bucossi, Serena, Mastromoro, Gioia, Ventriglia, Mariacarla, Simonelli, Ilaria, Tondolo, Vincenzo, Singh, Parminder, Kumar, Ashok, Pal, Amit, Rongioletti, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094789/ https://www.ncbi.nlm.nih.gov/pubmed/37047347 http://dx.doi.org/10.3390/ijms24076377 |
Ejemplares similares
-
Evaluation of zinc, copper, and Cu:Zn ratio in serum, and their implications in the course of COVID-19
por: Ivanova, Irena D., et al.
Publicado: (2022) -
Role of the Solute-Binding Protein CuaD in the Signaling and Regulating Pathway of Cellobiose and Cellulose Utilization in Ruminiclostridium cellulolyticum
por: Fosses, Aurélie, et al.
Publicado: (2023) -
Ceruloplasmin/Transferrin Ratio Changes in Alzheimer's Disease
por: Squitti, Rosanna, et al.
Publicado: (2010) -
Iron in Alzheimer’s Disease: From Physiology to Disease Disabilities
por: Pal, Amit, et al.
Publicado: (2022) -
Zinc Therapy in Early Alzheimer’s Disease: Safety and Potential Therapeutic Efficacy
por: Squitti, Rosanna, et al.
Publicado: (2020)